Annalisa Ariano

Annalisa Ariano

Auto-generated profile, based on publicly available information

Annalisa Ariano


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 June 2025 in The Journal of Liquid Biopsy
Verified
Journal Article
Open access
Caterina De RosaCaterina De Rosa
Caterina De Rosa
LALuisa Amato
Luisa Amato
AAAnnalisa Ariano
Annalisa Ariano
SCSara Capaldo
Sara Capaldo
Daniela EspositoDaniela Esposito
Daniela Esposito
Carminia Maria Della CorteCarminia Maria Della Corte
Carminia Maria Della Corte
The liquid biopsy (LB) represents a minimally invasive method for cancer screening that has been introduced in clinical practice for over a decade and that can accelerate treatment response assessment. LB allows the analysis of tumor cells or tumor-derived products (e.g. cell-free circulating nucleic acids, extracellular vesicles, and proteins) released from primary or metastatic tumor lesions into blood or other body fluids. In the era of immune-oncology, recent evidence indicates that tumor-specific immune responses can be detected in peripheral immune cells. The improvement of knowledge and the standardization of the isolation methods of these techniques will allow the detection and characterization of circulating tumor and immune biomarkers at an early stage as innovative tools to predict response to therapies. Nowadays, the analysis of peripheral blood mononuclear cells (PBMCs), circulating tumor cells (CTCs), peripheral blood-derived extracellular vesicles (EVs) and circulating tumor RNA (ctRNA) remains under-developed even if these non-invasive techniques can provide the complete genetic landscape of tumors and allow systematic tracking of cancer evolution. In addition, the evaluation of blood circulating cytokines, and early dynamics changes in the PBMCs of patients with solid tumors represent a promising area of research. Here, we present a comprehensive methodological framework for the evaluation of innovative peripheral blood-derived biomarkers. We also address the current challenges in isolation methods and analysis of PBMC, CTC, EVs and TEPs which are crucial for structuring the large amount of comprehensive information obtained from such samples, with the aim of advancing the translational cancer field.

Verified
Journal Article
Open access
PDF file
Hamid Heydari Sheikh HosseinHamid Heydari Sheikh Hossein
Hamid Heydari Sheikh Hossein
LALuisa Amato
Luisa Amato
VRViviana De Rosa
Viviana De Rosa
Caterina De RosaCaterina De Rosa
Caterina De Rosa
AAAnnalisa Ariano
Annalisa Ariano
FIFrancesca Iommelli
Francesca Iommelli
Background: Increased IL-1β levels may promote carcinogenesis and metastasis by affecting tumor biology and the tumor microenvironment (TME). In this context, extracellular vesicles (EVs) play a key role in cell-to-cell communication, thus modulating the TME and immune response. Here, we aimed to test whether tumor-derived small EVs (TEVs) isolated from sensitive and osimertinib-resistant (OR) non-small-cell lung cancer (NSCLC) cells may promote EMT via fibronectin binding to α5β1 integrin as well as suppress the immune system and if these effects may be favored by IL-1β. Methods: TEVs were isolated from control, OR, and IL-1β-stimulated NSCLC cells. Expressions of fibronectin and PD-L1 were screened in TEVs and the mRNA levels of vimentin and SMAD3 were also assessed in cancer cells after TEV co-culturing. Furthermore, to detect the effect on immune cells, we co-cultured TEVs with lung cancer patients’ peripheral blood mononuclear cells (PBMCs). Results: TEVs were positive for fibronectin and the highest protein levels were found in TEVs obtained from the OR and IL-1β-stimulated cells. TEV-mediated activation of α5β1 signaling led to the upregulation of vimentin and SMAD3 mRNA in NSCLC cells and stimulated cell migration. EVs also increased PD-1, CTLA-4, FOXP3, TNF-α, IL-12, and INF-γ mRNA in lung cancer patients’ immune cells. Conclusions: Our findings indicate that TEVs promote EMT in NSCLC cells by the activation of the fibronectin–α5β1 axis. Finally, IL-1β stimulation induces TEV release with biological properties similar to OR TEVs, thus leading to cancer invasion and immune suppression and suggesting that inflammation can promote tumor spreading.
1

25 November 2024 in Cancers
Verified
Journal Article
Open access
PDF file
LALuisa Amato
Luisa Amato
DODaniela Omodei
Daniela Omodei
Caterina De RosaCaterina De Rosa
Caterina De Rosa
AAAnnalisa Ariano
Annalisa Ariano
SCSara Capaldo
Sara Capaldo
VRViviana De Rosa
Viviana De Rosa
Background: Oncogene-driven NSCLC is usually treated with targeted therapies using tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways, affecting tumor survival and proliferation. EGFR- and KRAS-mutant NSCLCs are the most represented subtypes, and they are treated in clinical practice with oncogene-targeting drugs in the first and second line, respectively. Unfortunately, the development of oncogene-independent resistant clones limits TKI efficacy. Here, we used non-oncogene addiction (NOA) as an innovative therapeutic strategy to target other essential proteins that support changes in tumor phenotype. Specifically, we tested, for the first time, a combination of inhibitors, namely ATR, involved in DNA damage response, and pyruvate dehydrogenase kinases (PDKs), involved in energy metabolism. Methods: Sensitive PC9 and the corresponding EGFR-TKI-resistant PC9/OR, EGFR-mutant H1975, and KRAS-mutant A549 NSCLC cells, were treated with TKIs (osimertinib and selumetinib, respectively). In parallel, cells were exposed to two combination regimens: one using the TKI with an ATR inhibitor and the other one combining the two selected NOA inhibitors (ATR inhibitor, M4344; and PDK inhibitor, DCA). Results: The effect of these two combined approaches, compared to TKI alone, produced similar results in terms of cell proliferation, cell death, and migration. Thus, depending on tumor biology, selecting between the proposed therapeutic strategies will be different, to maximize tumor response. Conclusions: The major translational relevance of this study is to exploit new targets for the development of innovative and improved therapeutic strategies with NOA drugs, over combinations including target genes within the oncogene pathway, to overcome resistance to TKI therapies in patients with NSCLC who are oncogene-addicted.

19 November 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LALuisa Amato
Luisa Amato
DODaniela Omodei
Daniela Omodei
Caterina De RosaCaterina De Rosa
Caterina De Rosa
AAAnnalisa Ariano
Annalisa Ariano
SCSara Capaldo
Sara Capaldo
VRViviana De Rosa
Viviana De Rosa
Background: Oncogene-driven NSCLC are usually treated with targeted therapies using tyrosine kinase inhibitors (TKIs) to inhibit oncogene downstream signaling pathways thus affecting tumor survival and proliferation. EGFR and KRAS mutant NSCLC are the most represented subtypes and they are treated in clinical practice with oncogene-targeting drugs in first and second line, respectively. Unfortunately, the development of oncogene-independent resistant clones limits TKIs efficacy. Here, we used non-oncogene addiction (NOA) as an innovative therapeutic strategy to target other essential proteins that support changes in tumor phenotype. Specifically, we tested for the first time a combination of ATR, involved in DNA damage response, and pyruvate dehydrogenase kinases (PDKs), involved in energy metabolism, inhibitors. Methods: Sensitive PC9 and the corresponding EGFR-TKI-resistant PC9/OR, EGFR mutant H1975 and KRAS mutant A549 NSCLC cells were treated with TKIs (osimertinib and selumetinib, respectively). In parallel, cells were exposed to two combination regimens: one using the TKI with ATR inhibitor and the other one combining the two selected NOA inhibitors (ATR inhibitor, M4344 and PDK inhibitor, DCA). Results: The effect of these two combined approaches, compared to TKI alone, produced similar results in terms of cell proliferation, cell death and migration. Thus, depending on tumor biology, the selection among these proposed therapeutic strategies will be different to maximize tumor response. Conclusions: The major translational relevance of this study is to exploit new targets for innovative and improved therapeutic strategies with NOA drugs, over combinations including target genes within oncogenes pathway, to overcome resistance to TKI therapies in oncogene-addicted NSCLC patients.